Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dasotraline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 7/20 | 1.00 |
| ▸ | SLC6A4 known ✓ | P31645 | 7/20 | 1.00 |
| ▸ | SLC6A3 known ✓ | Q01959 | 7/20 | 1.00 |
| ▸ | MEN1 | O00255 | 4/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | MLNR | O43193 | 1/20 | 0.62 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.62 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.62 |
| ▸ | ESR1 | P03372 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.62 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.62 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.62 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.62 |
| ▸ | HTR1A | P08908 | 1/20 | 0.62 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.62 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.62 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Desmethylsertraline SCHEMBL29737233 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| Desmethylsertraline SCHEMBL29481074 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| Desmethylsertraline SCHEMBL4781834 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| Dasotraline SCHEMBL29690290 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| Desmethylsertraline SCHEMBL263132 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| Desmethylsertraline SCHEMBL9611184 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| Desmethylsertraline SCHEMBL260449 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| Desmethylsertraline SCHEMBL4570539 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| Desmethylsertraline SCHEMBL259292 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| Desmethylsertraline SCHEMBL29757858 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 196 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260131089-A1 | DRUG DELIVERY DEVICES AND METHODS FOR ADMINISTERING SUBSTANCES TO A BODY CAVITY BY HETEROGENOUS AEROSOLIZATION FOR TREATMENT OF BINGE-EATING DISORDERS AND/OR OBESITY | APTARGROUP, INC. (US) | 2026-05-14 | — | — | US | claimed |
| US-12491325-B2 | Drug delivery devices and methods for administering substances to a body cavity by heterogenous aerosolization for treatment of binge-eating disorders and/or obesity | APTARGROUP, INC. (US) | 2025-12-09 | — | — | US | claimed |
| EP-3630102-B1 | FORMULATIONS FOR TREATMENT OF POST-TRAUMATIC STRESS DISORDER | GLYTECH LLC (US) | 2024-08-14 | — | — | EP | claimed |
| US-11969431-B2 | Formulations for treatment of post-traumatic stress disorder | GLYTECH LLC (US) | 2024-04-30 | — | — | US | claimed |
| EP-4106872-A1 | COMPOSITIONS AND METHODS FOR ASSESSING THE EFFICACY OF INHIBITORS OF NEUROTRANSMITTER TRANSPORTERS | Denovo Biopharma LLC (US) | 2022-12-28 | — | — | EP | claimed |
| CN-115515680-A | Compositions and methods for assessing efficacy of neurotransmitter transporter inhibitors | 索元生物医药有限公司 | 2022-12-23 | — | — | CN | claimed |
| EP-1542961-B1 | TRANS 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-1-NAPTHALENAMINE FOR USE IN TREATMENT OF CNS DISORDERS | SEPRACOR INC (US) | 2013-09-11 | — | — | EP | claimed |
| US-20070282007-A1 | TREATMENT OF PAIN DISORDERS WITH trans 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-1-NAPHTHALENAMINE AND ITS FORMAMIDE | SEPRACOR INC. (US) | 2007-12-06 | — | — | US | claimed |
| US-20260131089-A1 | DRUG DELIVERY DEVICES AND METHODS FOR ADMINISTERING SUBSTANCES TO A BODY CAVITY BY HETEROGENOUS AEROSOLIZATION FOR TREATMENT OF BINGE-EATING DISORDERS AND/OR OBESITY | APTARGROUP, INC. (US) | 2026-05-14 | — | — | US | disclosed |
| US-12612661-B2 | Compositions and methods for assessing the efficacy of inhibitors of neurotransmitter transporters | DENOVO BIOPHARMA, LLC (US) | 2026-04-28 | — | — | US | disclosed |
| EP-4687890-A1 | METHODS FOR TREATING DEPRESSIVE STATES | BioXcel Therapeutics, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-12491325-B2 | Drug delivery devices and methods for administering substances to a body cavity by heterogenous aerosolization for treatment of binge-eating disorders and/or obesity | APTARGROUP, INC. (US) | 2025-12-09 | — | — | US | disclosed |
| US-12485088-B2 | Rapidly-orodispersible tablets having an interior cavity | Aprecia Pharmaceuticals LLC (US) | 2025-12-02 | — | — | US | disclosed |
| US-12324856-B2 | Oral drug dosage form comprising drug in the form of nanoparticles | Triastek, Inc. (CN) | 2025-06-10 | — | — | US | disclosed |
| US-20070282007-A1 | TREATMENT OF PAIN DISORDERS WITH trans 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-1-NAPHTHALENAMINE AND ITS FORMAMIDE | SEPRACOR INC. (US) | 2007-12-06 | — | — | US | disclosed |
| US-20070282007-A1 | TREATMENT OF PAIN DISORDERS WITH trans 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-1-NAPHTHALENAMINE AND ITS FORMAMIDE | SEPRACOR INC. (US) | 2007-12-06 | — | — | US | disclosed |
| US-20070282007-A1 | TREATMENT OF PAIN DISORDERS WITH trans 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-1-NAPHTHALENAMINE AND ITS FORMAMIDE | SEPRACOR INC. (US) | 2007-12-06 | — | — | US | disclosed |
| WO-2007115185-A2 | PREPARATION OF CHIRAL AMIDES AND AMINES | SEPRACOR INC. (US) | 2007-10-11 | — | — | WO | disclosed |
| WO-2007006797-A1 | USE OF 4-(3,4-DICHLORO-PHENYL)-1,2,3,4-TETRAHYDRO-NAPHTALEN-1-YLAMINE FOR TREATING CANCER | ANCERIS (FR) | 2007-01-18 | — | — | WO | disclosed |
| WO-2007006003-A2 | COMBINATIONS OF ESZOPICLONE AND TRANS 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-N-METHYL-1-NAPTHALENAMINE OR TRANS 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-1-NAPTHALENAMINE, AND METHODS OF TREATMENT OF MENOPAUSE AND MOOD, ANXIETY, AND COGNITIVE DISORDERS | SEPRACOR INC. (US) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260131089-A1 | DRUG DELIVERY DEVICES AND METHODS FOR ADMINISTERING SUBSTANCES TO A BODY CAVITY BY HETEROGENOUS AEROSOLIZATION FOR TREATMENT OF BINGE-EATING DISORDERS AND/OR OBESITY | CACNG6, MC5R, CRH | SLC6A2 782/4885SLC6A4 153/4885SLC6A3 384/4885 |
| US-20070282007-A1 | TREATMENT OF PAIN DISORDERS WITH trans 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-1-NAPHTHALENAMINE AND ITS FORMAMIDE | HTR4, HTR1D, HTR1A | SLC6A2 52/4885SLC6A4 21/4885SLC6A3 60/4885 |
| US-12324856-B2 | Oral drug dosage form comprising drug in the form of nanoparticles | CYP2D6, CYP3A5, CYP3A7 | SLC6A2 210/4885SLC6A4 268/4885SLC6A3 273/4885 |
| US-12612661-B2 | Compositions and methods for assessing the efficacy of inhibitors of neurotransmitter transporters | SLC6A4, SLC18A2, SLC6A2 | SLC6A2 3/4885SLC6A4 1/4885SLC6A3 5/4885 |
| US-12491325-B2 | Drug delivery devices and methods for administering substances to a body cavity by heterogenous aerosolization for treatment of binge-eating disorders and/or obesity | GCG, VAPA, GABRG2 | SLC6A2 719/4885SLC6A4 889/4885SLC6A3 291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.